Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11

Cancer Research

Volumn 58, Issue 1, 1998, Pages 20-22

  Danks, Mary K ^a   Morton, Christopher L ^a   Pawlik, Cynthia A ^a   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; DNA TOPOISOMERASE; IRINOTECAN; LOPERAMIDE; OCTREOTIDE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RHABDOMYOSARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIVER; PRODRUGS; RABBITS; RHABDOMYOSARCOMA; TUMOR CELLS, CULTURED;

EID: 0031975059     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86: 836-842, 1994.
2. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4194, 1991.
3. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
4. Tsuji, T., Kaneda, N., Kado, K., Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobio-Dyn., 14: 341-349, 1991.
5. Senter, P. D., Marquardt, H., Thomas, B. A., Hammock, B. D., Frank, I. S., and Svensson, H. P. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res., 56: 1471-1474, 1996.
6. Satoh, T., Hosokawa, M., Atsumi, R., Suzuki, W., Hakusui, H., and Nagai, E. Metabolic activation of CPT-11,7-ethyl-10-[4-(-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm Bull 17: 662-664, 1994.
7. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyi-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
8. Armand, J. P. Irinotecan (CPT11): recent clinical development and future direction. Ann. Oncol., 5: (Suppl. 5): 163, 1994.
9. Cascinu, S. Management of diarrhea induced by tumors or cancer therapy. Curr. Opin. Oncol., 7: 325-329, 1995.
10. Harris, A. G., O'Dorisio, T. M., Woltering, E. A., Anthony, L. B., Burton, F. R., Geller, R. B., Grendell, J. H., Levin, B., and Redfern, J. S. Consensus statement: octreotide dose titration in secretory diarrhea: Diarrhea Management Consensus Development Panel. Dig. Dis. Sci., 40: 1464-1473, 1995.
11. Douglass, E. C., Valentine, M., Etcubanas, E., Parham, D. M., Webber, B. L., Houghton, P. J., Houghton, J. A., and Green, A. A. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet. Cell Genet., 45: 148-155, 1987.
12. Rees, S., Coote, J., Stables, J., Goodson, S., Harris, S., and Lee, M. G. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibioticresistant cells to express recombinant protein. Biotechniques, 20: 102-110, 1996.
13. Stewart, C. F., Zamboni, W. C., Crom, W. R., and Houghton, P. J. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother. Pharmacol., 40: 259-265, 1997.
14. Barilero, I., Gandia, D., Armand, J. P., Mathieu-Boue, A., Re, M., Gouyette, A., and Chabot, G. G. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr., 575: 275-280, 1992.
15. Miller, S. B., Main, A. R., and Rush, R. S. Purification and physical properties of oligomeric and monomeric carboxylesterases from rabbit liver. J. Biol. Chem., 255: 7161-7167, 1980.
16. Satoh, T., and Hosokawa, M. Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Toxicol. Lett., 82/83: 439-445, 1995.
17. Lokiec, F., Monegier du Sorbier, B., and Sanderink, G-J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 2: 1943-1949, 1996.
18. Trinh, O. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res., 55: 4808-4812, 1995.